United States: PTAB Puts Method Of Treatment Patents Under The 101 Knife

While the Supreme Court decisions in Myriad and Mayo have been applied to diagnostic-type claims, method of treatment patents were thought to be safe from the recent judicial expansion of the patent-(in)eligibility doctrine. However, several decisions from the USPTO Patent Trial and Appeal Board (PTAB) have found personalized method of treatment claims ineligible under Mayo. Did the Supreme Court really intend to put such methods under the 35 U.S.C. § 101 knife?

The USPTO Patent Eligibility Guidelines

The USPTO Patent Eligibility Guidelines for examiners includes an example that relates to the diagnosis and treatment of a fictitious disease called "julitis" based on the detection of a newly identified protein marker called JUL-1. The guidance indicates that the following method of treatment claims withstand scrutiny under § 101:

A method of treating a patient with julitis, the method comprising administering an effective amount of anti-TNF antibodies to a patient suffering from julitis.

A method of diagnosing and treating julitis in a patient, said method comprising:
a. obtaining a plasma sample from a human patient;
b. detecting whether JUL-1 is present in the plasma sample;
c. diagnosing the patient with julitis when the presence of JUL-1 in the plasma sample is detected; and
d. administering an effective amount of anti-tumor necrosis factor (TNF) antibodies to the diagnosed patient.

Notably, these claims are found to be patent-eligible even though (i) the JUL-1 protein is naturally correlated with julitis (but the correlation was not previously known) and (ii) anti-TNF antibodies are both a "nature-based product" and a "conventional" therapy for julitis.

Patent eligibility is found for the first claim because the "administering" step does not implicate any § 101 issues, and the claim as a whole is "focused on a process of practically applying the [nature-based] product to treat a particular disease, and not on the product per se."

Patent eligibility is found for the second claim because steps a, b and d place "meaningful limits on the use of the ... correlation and critical thinking step" (step c). Thus, "[t]he totality of these steps including the recitation of a particular treatment ... amount to more than merely diagnosing a patient with julitis and instructing a doctor to generically 'treat it.'" The guidelines also not that "the combination of steps, which is not routine and conventional, ensures that patients who have julitis will be accurately diagnosed ... and properly treated."

Although the guidelines are not legally binding on the PTAB, it is disconcerting that the PTAB is dismissing them out of hand and rendering inconsistent decisions in ex parte appeals, as illustrated by the decisions outlined below.

Ex Parte Chettier

The claims at issue in Ex parte Chettier (Appeal No. 2016-003639) (decided Aug. 25, 2016) were directed to personalized methods of treating patients carrying newly discovered genetic markers associated with degenerative disc disease (DDD). The appealed independent claim is set forth below:

A method comprising applying at least one DDD condition therapeutic to a patient based on at least one DDD altered risk associated biological marker determined to be present in said patient.

On its face, the claim appears similar to the method of treatment claims deemed to satisfy § 101 in the USPTO's julitis example, since it relates to a method of treatment that involves using a newly discovered marker to identify a patient population for treatment with a conventional therapy. Like the julitis claims, the Chettier claim as a whole seems focused on practically applying a natural correlation to treat a particular disease, and not on the natural correlation per se. Yet, the PTAB dismissed the USPTO's Eligibility Guidelines out of hand, and found the claims to be invalid by analogy to the claims at issue in Mayo:

Appellants also argue that the claims pass muster under the USPTO's 2014 Interim Eligibility Guidelines. (Appeal Br. 13-16.) However, as Appellants themselves acknowledge, the Guidelines "are not law." (Id. at 13.) The Supreme Court's interpretation of§ 101, on the other hand, is controlling case law, and under the standard set out in Mayo, claim 68 is not a patent-eligible method.

The PTAB compared the Chettier claim to those at issue in Mayo, and determined that "the addition of this conventional [treatment] step to the natural phenomenon or law of nature (a genetic marker associated with altered DDD risk) does not 'transform unpatentable natural correlations into patentable applications of those regularities.'"

Would method of treatment claims reciting a more specific, but still conventional "DDD condition therapeutic" have fared any differently?

Ex Parte Atwood

The claims at issue in Ex parte Atwood (Appeal No. 2015-001611) (decided Aug. 16, 2016) were directed to personalized methods of treating Alzheimer's patients based on newly identified genetic risk factors. A representative independent claim is set forth below:

A method comprising administering treatment to a patient at risk for developing Alzheimer's disease (AD) or a patient diagnosed with AD, wherein the patient is homozygous or heterozygous for an Apolipoprotein E4 (APOE4) allele, and the patient has a single nucleotide polymorphism (SNP)...rs4073366, wherein the patient is homozygous for the cytosine allele (C-allele) or the patient is homozygous for the guanine allele (G-allele) at the polymorphic position of rs407336 ....

Again, the claim seems similar to the patent-eligible julitis claim, but again, the PTAB concluded that the claims do not "add enough" to the discovered natural correlation to satisfy § 101 under Mayo. In particular, the PTAB found:

Appellant's claimed method does no more than identify a sub-population of patients with, or at risk of developing, AD and then administer exactly the same treatment to those patients as was done in the prior art for the entire population of patients with, or at risk of developing, AD. .... Appellant's therapy administration step is not based on any identified correlation, because patients are administered exactly the same treatment regimen suggested by the prior art for any AD patient.

In reaching its decision, the PTAB noted the general nature of the treatment step, leaving open the possibility that claims directed to treating a specific patient population with a specific therapeutic regimen might be found to satisfy § 101.

Ex Parte Chamberlain

The claims at issue in Ex parte Chamberlain (Appeal No. 2014-009849) (decided Jan. 20, 2017) related to personalized methods of treating a bone disorder based on a newly discovered association between a genetic polymorphism and increased risk of bone disorder. A representative claims is as follows:

A method of treating osteoporosis in a human individual having a BMD T score of -1 or less, the method comprising:
determining in a nucleic acid sample obtained from the individual, the presence of a TT genotype at single nucleotide polymorphism rs2297480 (SNP rs2297480) in the farnesyl diphosphate synthase (FDPS) gene,
wherein the presence of the TT genotype is determined by hybridizing the nucleic acid sample to a nucleic acid probe which comprises SEQ ID NO: 1 or the complement thereof; wherein the probe or the nucleic acid sample is immobilized in a nucleic acid array, and;
administering intravenous [pamidronate] to the individual if the TT genotype is present in the sample.

These claims seem to hew even more closely to the patent-eligible julitis claims, since they recite a specific treatment. However, the PTAB found them ineligible under the two-step analytical framework outlined in Mayo:

[A]s to part one of the Supreme Court's test, Appellants' claim 1 is expressly directed to the law of nature discovered by Appellants—that the presence of the TT genotype at SNP rs2297480 is indicative that an individual having a bone disorder will respond to treatment with bisphosphonates.

As to part two of the Supreme Court's test, the only other step in Appellants' claim 1, administering bisphosphonate to the individual having the bone disorder, is a well understood and routine treatment step for such patients, as explained in Appellants' Specification. See Spec. 1 ("Oral bisphosphonates are the commonest first-choice treatment where a reduction in osteoclasis would be beneficial, for example, for post-menopausal osteoporosis .....").

Thus, at least in this case, reciting a specific, conventional treatment did not spare these personalized method of treatment claims from the § 101 knife.

Can We Get A Second Opinion?

Although the claims before the Supreme Court in Mayo included an "administering" step, the invention at issue was not directed to a method of treatment, but rather provided a method for optimizing the dose of a conventional treatment. Indeed, in Mayo the Supreme Court seemed to carve out method of treatment patents when it distinguished the claims before it from "a typical patent on a new drug or a new way of using an existing drug." Subsequently in Myriad, the Supreme Court again distinguished the claims before it from method claims and "patents on new applications of knowledge about the BRCA1 and BRCA2 genes."

Following these leads, the Federal Circuit noted in Rapid Litigation Management v. Cellzdirect (albeit in dicta) that method of treatment claims "recite processes to achieve a desired outcome," and therefore are patent eligible. Thus, there is at least a chance–if not a likelihood–that the Federal Circuit would uphold personalized method of treatment claims similar to those the PTAB denied under § 101.

While stakeholders may be eager for more guidance on this issue, it could take some time before the Federal Circuit has an opportunity to weigh in on the eligibility of personalized method of treatment claims, and even longer for the Supreme Court to give a more definitive "second opinion." Until then, Applicants will have to convince examiners and/or the PTAB that their personalized method of treatment claims indeed "add enough" under Mayo to warrant the patent protection that can foster investment and innovation in personalized medicine.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions